GeoVax Labs (NASDAQ:GOVX) Issues Earnings Results, Beats Expectations By $1.19 EPS

GeoVax Labs (NASDAQ:GOVX) posted its quarterly earnings data on Monday. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.16) by $1.19, FiscalAI reports.

GeoVax Labs Stock Up 3.9%

Shares of NASDAQ:GOVX traded up $0.03 during midday trading on Monday, reaching $0.76. The company’s stock had a trading volume of 170,514 shares, compared to its average volume of 2,345,560. The firm has a market cap of $2.64 million, a price-to-earnings ratio of -0.04 and a beta of 3.68. GeoVax Labs has a 1 year low of $0.69 and a 1 year high of $20.62. The business has a 50 day moving average price of $1.55 and a 200 day moving average price of $1.84.

Hedge Funds Weigh In On GeoVax Labs

Several large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in GeoVax Labs in the 1st quarter valued at about $27,000. HRT Financial LP acquired a new position in shares of GeoVax Labs during the 4th quarter valued at about $31,000. Armistice Capital LLC purchased a new position in shares of GeoVax Labs during the 3rd quarter worth about $253,000. Finally, Renaissance Technologies LLC purchased a new position in shares of GeoVax Labs during the 4th quarter worth about $104,000. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GOVX has been the topic of several analyst reports. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $150.00.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.